V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 250010551 | 250007753 | 0 | null | Adjuvant (A) | 2017-06-10 | 2017-07-09 | Nilotinib | N | N | 250030757 | DASATINIB |
| 250010552 | 250010882 | 1.7 | 61.2 | Curative (C) | 2016-02-24 | 2016-02-24 | GemCarbo Days 1+8 | 02 | N | 250030761 | FLAG + IDARUBICIN |
| 250010553 | 250007756 | 1.67 | null | Curative (C) | 2017-02-02 | 2017-04-18 | SPIRE Trial | N | N | 250030776 | PEG INTERFERON |
| 250010554 | 250007758 | 1.77 | 0 | Disease modification (D) | 2015-11-22 | 2015-12-05 | Cytarabine Low Dose | N | N | 250030780 | NILOTINIB |
| 250010555 | 250007759 | null | 64.6 | Palliative (P) | null | 2016-08-18 | LEAM | 2 | N | 250030794 | CYTARABINE + MITOXANTRONE |
| 250010556 | 250007759 | 1.63 | null | Disease modification (D) | null | 2015-10-01 | IPM | N | N | 250030794 | FLUDARABINE + MELPHALAN |
| 250010557 | 250007761 | 1.73 | 59.9 | Disease modification (D) | 2014-08-23 | 2014-08-23 | IMATINIB | null | N | 250030809 | ANAGRELIDE |
| 250010558 | 250007762 | 1.72 | null | Palliative (P) | 2018-05-27 | 2018-08-13 | GEMCARBO | N | N | 250030817 | CARBOPLATIN + VINORELBINE |
| 250010560 | 250012109 | null | null | Palliative (P) | 2018-02-06 | 2018-02-06 | Dasatinib | 02 | N | 250030824 | MPV |
| 250010561 | 250012109 | 1.62 | null | Curative (C) | null | 2016-10-23 | Rituximab | 02 | N | 250030824 | PEG INTERFERON |
| 250010562 | 250007770 | 1.59 | 88.9 | Disease modification (D) | 2017-11-16 | 2017-12-11 | Bortezomib + Cyclophos + Dex | N | N | 250030848 | BUSULPHAN |
| 250010563 | 250007771 | 1.61 | null | Palliative (P) | 2014-01-01 | 2014-01-07 | IMATINIB | N | N | 250030853 | TRASTUZUMAB |
| 250010564 | 250007772 | 1.59 | 95.7 | Palliative (P) | 2016-06-09 | 2017-07-04 | Bendamustine+Rituximab(Sub Courses) | N | N | 250030855 | IPM |
| 250010565 | 250007775 | 1.63 | 70.5 | Palliative (P) | 2016-07-01 | 2016-07-08 | Palbociclib | N | N | 250030856 | RITUXIMAB |
| 250010566 | 250007778 | null | null | Palliative (P) | 2016-02-11 | 2016-03-05 | FLAG + Idarubicin | N | N | 250030868 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 250010567 | 250007780 | 1.8 | 0 | Disease modification (D) | 2012-07-23 | 2013-06-25 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | 250030872 | ABVD |
| 250010568 | 250010890 | null | null | Palliative (P) | 2018-11-29 | 2018-11-29 | null | null | N | 250030886 | AZACITIDINE |
| 250010569 | 250010890 | null | null | Palliative (P) | 2014-12-10 | 2014-12-10 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 01 | N | 250030886 | CARBOPLATIN + VINORELBINE |
| 250010570 | 250007781 | null | null | Palliative (P) | 2014-04-27 | 2014-04-27 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 250030911 | CHOP R |
| 250010571 | 250007782 | 1.53 | 0 | Palliative (P) | 2013-10-06 | 2013-10-06 | Bevacizumab | null | N | 250030913 | INTERFERON |
| 250010572 | 250007783 | 1.67 | 128 | Curative (C) | 2016-07-15 | 2016-07-15 | PEG INTERFERON | N | null | 250030914 | DASATINIB |
| 250010573 | 250010893 | 1.8 | null | Disease modification (D) | 2016-06-07 | 2016-06-07 | Bevacizumab | 2 | N | 250030916 | ANAGRELIDE |
| 250010574 | 250007785 | null | null | Adjuvant (A) | 2014-06-14 | 2014-06-30 | AML 19 TRIAL | N | N | 250030917 | NILOTINIB |
| 250010575 | 250007788 | 1.81 | 70.5 | Disease modification (D) | 2014-09-03 | 2015-03-21 | Triple Intrathecal | N | null | 250030918 | BORTEZOMIB + THALIDOMIDE |
| 250010576 | 250007792 | 1.71 | null | Disease modification (D) | 2017-08-04 | 2017-08-04 | Azacitidine | 02 | N | 250030922 | DASATINIB |
| 250010577 | 250007793 | null | null | Palliative (P) | 2016-04-02 | 2016-04-02 | CHLORAMBUCIL + OFATUMUMAB | N | null | 250030923 | EPIRUBICIN |
| 250010578 | 250007794 | 1.69 | null | Palliative (P) | 2014-11-24 | 2014-12-22 | IMATINIB | 2 | N | 250030938 | IMATINIB |
| 250010579 | 250007794 | 0 | 70.5 | Not known (9) | 2016-11-16 | 2016-12-02 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | 02 | N | 250030938 | AZACITIDINE |
| 250010580 | 250007794 | 0 | 70.8 | Curative (C) | 2014-06-04 | 2014-06-04 | IMATINIB | N | N | 250030938 | ANAGRELIDE |
| 250010581 | 250007794 | null | null | Curative (C) | 2017-05-03 | 2017-05-03 | Cisplatin + Vinorelbine (IV) | N | N | 250030938 | AML18 TRIAL |
| 250010582 | 250007795 | 1.68 | 73 | Disease modification (D) | 2016-11-19 | 2016-12-31 | Cisplatin | N | N | 250030977 | EVEROLIMUS |
| 250010583 | 250007796 | 1.8 | 0 | Palliative (P) | 2017-03-02 | 2017-03-02 | BUSULFAN | N | N | 250030979 | CTD |
| 250010584 | 250007798 | 1.82 | 62 | Adjuvant (A) | 2018-06-30 | 2018-06-30 | CHOP R - 21 days | 02 | N | 250031012 | DASATINIB |
| 250010585 | 250010896 | null | null | null | 2016-05-22 | 2016-05-22 | PEMBROLIZUMAB | N | N | 250031012 | ANAGRELIDE |
| 250010586 | 250007799 | null | null | Disease modification (D) | 2017-09-18 | 2017-10-16 | ABVD | N | N | 250031023 | BENDAMUSTINE + RITUXIMAB |
| 250010587 | 250010897 | null | 78.1 | Curative (C) | 2013-11-19 | 2013-11-19 | AML 19 TRIAL | null | N | 250031023 | BUSULPHAN |
| 250010588 | 250007801 | 1.8 | 0 | Palliative (P) | 2016-12-30 | 2016-12-30 | IPM | N | N | 250031030 | R-GEM-P |
| 250010589 | 250007801 | 1.76 | 70.2 | Disease modification (D) | 2016-06-11 | 2016-06-11 | Nilotinib | N | null | 250031030 | PEG INTERFERON |
| 250010590 | 250007803 | null | 57.4 | Palliative (P) | 2017-08-12 | 2017-08-27 | IGEV | 2 | N | 250031038 | ANAGRELIDE |
| 250010591 | 250007803 | 1.65 | 117 | Palliative (P) | 2014-06-03 | 2014-06-03 | BORTEZOMIB + THALIDOMIDE | 2 | N | 250031038 | RITUXIMAB |
| 250010592 | 250012115 | 1.65 | 0 | null | 2017-09-10 | 2017-09-10 | Folfirinox | 02 | N | 250031048 | NOT MATCHED |
| 250010593 | 250012591 | null | 51.9 | Palliative (P) | 2015-12-15 | 2016-03-22 | BOSUTINIB | N | N | 250031056 | NOT MATCHED |
| 250010595 | 250007805 | 1.78 | 64 | Disease modification (D) | 2015-09-17 | 2015-09-17 | Rituximab | 2 | N | 250031082 | BUSULPHAN |
| 250010596 | 250007805 | null | null | Curative (C) | 2015-06-01 | 2015-06-03 | Rituximab | N | N | 250031082 | BENDAMUSTINE + RITUXIMAB |
| 250010597 | 250007806 | 0 | 85 | Curative (C) | 2014-08-02 | 2014-08-09 | BENDAMUSTINE + RITUXIMAB | 2 | N | 250031086 | TRASTUZUMAB |
| 250010598 | 250007807 | null | 99 | Disease modification (D) | 2013-09-28 | 2013-09-28 | CISPLATIN + GEMCITABINE + RITUXIMAB | N | null | 250031089 | PAD |
| 250010599 | 250007808 | null | 66.899 | Adjuvant (A) | 2017-03-22 | 2017-04-11 | Shamash LBCMVD-56 | 02 | N | 250031094 | PALBOCICLIB |
| 250010600 | 250010903 | 1.63 | 80.8 | Disease modification (D) | 2014-06-15 | 2014-06-15 | Azacitidine | 02 | N | 250031096 | CVD |
| 250010601 | 250007809 | null | null | null | null | 2015-02-06 | PEG INTERFERON | N | N | 250031099 | TRASTUZUMAB |
| 250010602 | 250012592 | null | 66.899 | Curative (C) | 2016-02-09 | 2016-02-09 | Trastuzumab Subcutaneous | N | N | 250031099 | GEMCITABINE |